Organogenesis Holdings Inc. — Third Quarter 2026 Earnings Summary

Organogenesis Holdings Inc. reported a third quarter 2026 net loss of $29.6 million, a significant reversal from the $21.6 million net income recorded in the same period of 2025. Total net revenue for the quarter fell to $45.5 million, down 70% from $150.5 million in the prior year, driven primarily by a 73% decline in Advanced Wound Care sales. The company's cash and cash equivalents decreased to $21.3 million as of September 30, 2026, from $93.7 million at the end of 2025. For the full fiscal year 2026, the company revised its total net revenue guidance to a range of $179.4 million to $200.0 million, reflecting a projected decline of 65% to 68% compared to 2025.